BCLAF1

Across TCGA pan-cancer cohorts, BCLAF1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCLAF1 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BCLAF1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BCLAF1 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

HNSC, COAD, and LUAD are the cancer types where BCLAF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.624	0.828	.010	32	view →
COAD	DFS	Median	All	1.000	0.887	.021	12	view →
LUAD	OS	Median	All	1.000	0.754	.002	12	view →
GBM	OS	Tertile	All	0.510	0.247	.003	10	view →
LSCC	OS	Quartile	All	1.000	0.771	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BCLAF1–HNSC (OS)

Open the HNSC breakdown →